“Every leaf that grows will tell you:

what you sow will bear fruit,

so if you have any sense my friend,

don’t plant anything but Love.”

— Rumi —

The MOCA Story

Summary of Key Points


Medicinal Organic Cannabis Australia (MOCA) is the first established organic cannabis company in Australia, with a focus on ethically sourced organic products.


  • Licenced: Australian import, export and wholesale licences for Medical Cannabis. European approvals and subsidies to cultivate in Europe.

  • Products Approved: 21 products approved in Australia by the Therapeutic Goods Administration (TGA).

  • Import Permits: Australian import permits from the Office of Drug Control for all its products.

  • Products: has an approved range of MOCA branded organic cannabis products & has developed a new product that could reduce patient costs by 30%.

  • Distribution: has supply agreements with pharmacies and practitioners in Australia.

  • Team: is science based with 4 PhD’s on the team to ensure product quality and standard. MOCA is focused on leveraging digital marketing channels. Has global third party warehousing and logistics suppliers in Australia.

  • International opportunities: were finalists in 2 international tenders to supply cannabis (Italy & Barbados).

  • Facilities: has a 15 year lease on a 18,000m2 cultivation facility in Italy with subsidised water and energy costs.

  • Cannabis Clinic: MOCA launched its cannabis clinic in March 2022 with the focus on Telehealth to service the Australian market.


Who are we?


Medicinal Organic Cannabis Australia (MOCA) Pty Ltd was founded in March 2017 and incorporated in June 2017. Australian State and Federal medical cannabis import, export and wholesale licences were awarded to MOCA in 2018.

Directors, Alessandro Sorbello and Emanuela Ispani, founded the Company following changes to Australian legislation. The directors commenced with scientific research to develop MOCA’s product range. MOCA now has four PhD’s on the team and has converted its knowledge base to develop a product range of 21 organic medicines. Ten products developed by our scientific team under the MOCA brand and 11 products sourced from third party manufacturers, including CBDfx and Stanley Brothers.


All our products are approved by the Australian Federal Government (TGA) and can be prescribed by medical practitioners to treat a range of conditions including:

  • chronic pain

  • anxiety

  • chemotherapy-induced nausea and vomiting

  • epilepsy

  • palliative care indications

  • cancer pain

  • spasticity from neurological conditions

  • anorexia and other conditions.

The three key gateways to importing and supplying medical cannabis medicines by wholesale in Australia are:

  1. State and Federal Government licenses to import and wholesale

  2. Import permits from the Office of Drug Control (ODC)

  3. Product approvals by the TGA

MOCA has all three gateways approved with licences, permits and approvals in hand.

In conjunction with international standards, MOCA has developed proprietary production and manufacturing protocols and procedures. These operational methods of operation are approved at State and Federal level by the New South Wales Ministry of Health and the Office of Drug Control (ODC). They are designed to manage and meet its extensive regulatory compliance for the storage and handling of medical cannabis products.

These protocols mean that MOCA is ‘hands free’ and our entire process for transport, storage and distribution of our products are handled by specialised global pharmaceutical contractors in their logistics centre. This process eliminates the need for expensive proprietary warehousing costs and logistics staff, thus significantly reducing the Company’s operating costs to supply the products to medical professionals.

In September 2020, the TGA announced the Therapeutic Goods Administration (TGA) announced an interim decision to reclassify cannabidiol (CBD) products so they can be purchased over-the-counter at pharmacies. Reference The TGA interim decision to create a new Schedule 3 (Pharmacist Only Medicine) entry for cannabidiol (CBD) at doses up to 60 mg/day or less.

This works very much to MOCA’s advantage. We have 4 products in our approved range that meet this new rescheduling criteria and that we can supply directly to pharmacists. We view this as an excellent opportunity to sell significant quantities of our products into our partner pharmacies before the end of the year.

In Australia, medical practitioners and patients are rapidly accepting cannabis as a natural and effective treatment for a broad range of health issues. The Company is focused on supplying the growing demand in Australia for organic, whole plant medical cannabis products.

The Company has developed cannabis products that are both high quality and cost effective, in the belief that plant based medicine should be accessible. To this end, MOCA has created a new whole plant ‘infusion’ product range that could significantly reduce the cost to customers by 30% of current retail prices.

MOCA currently has a selected number of shareholders. The Company works on tight operation overheads and daily running costs and is very agile and responsive to changes in markets and legislation.

Right now we are focused on our database of 400 natural health practitioners, pharmacies and doctors that have experience with medicinal cannabis and therefore are a ready audience. Selling our products to this database of medical professionals requires that we build a Sales team on the ground in Australia that can promote and sell our products.


Our Responsibilities

  • Our first responsibility is to the doctors, nurses, and patients, to mothers and fathers and all others who will use our products and services.

  • Secondly, we are responsible to our employees who work with us throughout the world.

  • Thirdly, we are responsible to the communities in which we live and work and to the world community at large.

  • Our final responsibility is to our shareholders.

Our Approach to Manufacturing Products


We consider the ‘Triple Bottom line’ (People, Planet, Profit) the ethical measure of business. MOCA’s investment principle determines the impact on the environment, the social perspective, and our corporate governance.

Whilst our current focus is on manufacturing and importing medical cannabis products, we are oriented on the entire ‘seed to sale’ process. At MOCA we believe that planting with appropriate organic practices can heal the soil and the earth and thus in turn, can heal its populace. MOCA works with cultivators and purchases raw materials for manufacture, without intermediaries.

It is for this reason that we influence and control the entire process from soil preparation to genetic selection to cultivation and harvest to manufacturing and wholesale.

Our aim is to offer a viable, affordable, plant based solution based on ethical practices. MOCA expands the traditional reporting framework to take into account social and environmental performance in addition to financial performance.